China halts sale of Sun Pharma drug used to treat dementia

China's medicine regulator has halted the import, sale, and use of Sun Pharmaceutical Industries' dementia drug, rivastigmine hydrogen tartrate capsules. A recent inspection revealed production process shortcomings, including contamination prevention and quality management issues. This follows a 2024 warning letter from the U.S. FDA regarding similar manufacturing practice violations at the same Indian site.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TwltGCH
via IFTTT